Arcus Biosciences, Inc. Other Comprehensive Income (Loss), Net of Tax
Arcus Biosciences, Inc. (RCUS) reported Other Comprehensive Income (Loss), Net of Tax of -$1.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$1.00M.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $2.00M, a 100.00% increase year-over-year.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was -$1.00M, a 133.33% decline year-over-year.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $1.00M.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $7.00M.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$6.00M.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$1.00M.
- Arcus Biosciences, Inc. other comprehensive income (loss), net of tax for fiscal 2020 was -$20.00K, a 111.70% decline from fiscal 2019.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | -$1.00M 10-Q · filed 2026-08-05 | |||||
| 2024-09-30 | $2.00M 10-Q · filed 2025-10-28 | |||||
| 2024-03-31 | -$1.00M 10-Q · filed 2025-10-28 | |||||
| 2023-12-31 | $7.00M 10-K · filed 2026-02-25 | |||||
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-06 | |||||
| 2023-03-31 | $3.00M 10-Q · filed 2024-11-06 | |||||
| 2022-12-31 | -$6.00M 10-K · filed 2025-02-25 | |||||
| 2022-09-30 | -$2.00M 10-Q · filed 2023-11-07 | -$2.56M 10-Q · filed 2022-11-02 | -$4.00M derived: sum of 2 quarters · filed 2023-11-07 | -$8.00M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | -$2.00M 10-Q · filed 2023-11-07 | -$2.58M 10-Q · filed 2022-08-03 | -$6.00M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | -$4.00M 10-Q · filed 2023-11-07 | -$3.40M 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | -$1.00M 10-K · filed 2024-02-21 | -$1.30M 10-K · filed 2022-02-23 | ||||
| 2021-09-30 | -$46.00K 10-Q · filed 2022-11-02 | -$90.00K derived: sum of 2 quarters · filed 2022-11-02 | -$136.00K derived: sum of 3 quarters · filed 2022-11-02 | |||
| 2021-06-30 | -$44.00K 10-Q · filed 2022-11-02 | -$90.00K derived: sum of 2 quarters · filed 2022-11-02 | ||||
| 2021-03-31 | -$46.00K 10-Q · filed 2022-11-02 | |||||
| 2020-12-31 | -$20.00K 10-K · filed 2022-02-23 | |||||
| 2020-09-30 | -$63.00K 10-Q · filed 2021-11-08 | -$207.00K derived: sum of 2 quarters · filed 2021-11-08 | $17.00K derived: sum of 3 quarters · filed 2021-11-08 | |||
| 2020-06-30 | -$144.00K 10-Q · filed 2021-11-08 | $80.00K derived: sum of 2 quarters · filed 2021-11-08 | ||||
| 2020-03-31 | $224.00K 10-Q · filed 2021-11-08 | |||||
| 2019-12-31 | $171.00K 10-K · filed 2022-02-23 | |||||
| 2019-09-30 | -$60.00K 10-Q · filed 2020-11-05 | $24.00K derived: sum of 2 quarters · filed 2020-11-05 | $160.00K derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $84.00K 10-Q · filed 2020-11-05 | $220.00K derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $136.00K 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | -$65.00K 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | -$25.00K 10-Q · filed 2019-11-05 | -$11.00K derived: sum of 2 quarters · filed 2019-11-05 | -$66.00K derived: sum of 3 quarters · filed 2019-11-05 | |||
| 2018-06-30 | $14.00K 10-Q · filed 2019-11-05 | -$41.00K derived: sum of 2 quarters · filed 2019-11-05 | ||||
| 2018-03-31 | -$55.00K 10-Q · filed 2019-11-05 | |||||
| 2017-12-31 | -$16.00K 10-K · filed 2019-03-05 | |||||
| 2016-12-31 | -$26.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |